HCW Biologics HCWB 深 沪
已收盘 10-10 16:00:00 美东时间
4.06
-0.480
-10.57%
华盛通- 最 高4.595
- 今 开4.55
- 成交量 5.96万股
- 最 低 4.05
- 昨 收 4.54
- 总市值 873.55万
- 52周最高 100.80
- 市盈率 静 --
- 换手率 2.77%
- 52周最低 2.77
- 委 比 68.85%
- 总股本 215.16万
- 历史最高 311.00
- 量 比 0.23
- 振 幅 12.00%
- 历史最低 4.05
- 每 手 1
- 风险率 7.01%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program
HCW Biologics Inc. announced advancements in its second-generation T-Cell Engager (TCE) program, addressing challenges of the first generation such as manufacturing complexity and safety concerns. The program demonstrates improved manufacturability, safety profile, and efficacy against solid tumors, positioning the company among innovative biotech firms. Dr. Peter Rhode discussed these developments in a Virtual Investor segment, highlighting the ...
09-30 12:45
HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing
HCW Biologics congratulates Wugen on securing a $115 million equity financing led by Fidelity, with HCW holding a minority stake in Wugen from their 2020 license agreement. The Company has generated $16.2 million in revenues through this partnership. HCW, focused on immunotherapies for inflammation-related diseases, highlights Wugen's advancements in CAR-T cell therapies. Wugen, based in St. Louis, is pioneering off-the-shelf cell therapies for h...
09-18 13:15
HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development
HCW Biologics announced positive preclinical data for its lead product candidate, HCW11-040, a multi-functional fusion protein combining pembrolizumab (Keytruda), IL-7, IL-15, and TGF-β traps. The molecule demonstrated superior immune-cell activation, tumor infiltration, and anti-tumor effects compared to pembrolizumab alone, while avoiding cytokine storm risks. HCW Biologics plans to advance HCW11-040 into late IND-enabling studies for potential...
09-16 12:00
Why Is HCW Biologics Stock Surging 102% Overnight?
HCW Biologics' stock jumped 102.72% to $6.73 after the company revealed the successful development of second-generation T-cell engagers for solid tumors.
09-12 13:27
HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program
HCW Biologics developed second-generation T-cell engagers (TCEs) targeting solid tumors using its proprietary TRBC platform, addressing challenges faced by first-generation TCEs. Preclinical studies showed these TCEs effectively target cancer antigens, activate effector T cells, and reduce tumor-induced immunosuppression. A non-human primate safety study demonstrated high tolerability at efficacious doses without serious side effects. The Company...
09-09 12:00
Analysts Offer Insights on Healthcare Companies: HCW Biologics (HCWB) and Century Therapeutics (IPSC)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
09-08 16:20
HCW Biologics Extends License Fee Payment Deadline
HCW Biologics ( ($HCWB) ) has issued an announcement. HCW Biologics Inc. and WY...
09-06 04:57
Robert F. Kennedy Jr.'s Vaccine Shake-Up Sparks Coast-To-Coast Divide: West Coast Creates Health Alliance, Florida Rolls Back Requirements
California, Oregon and Washington form regional vaccine alliance to counter federal guidance under Robert F. Kennedy Jr. as Florida eliminates state mandates.
09-04 15:04
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Invivyd (NASDAQ:IVVD) stock increased by 132.3% to $1.3 during Tuesday...
08-26 20:09
HCW Biologics Stock Rockets 55% on Cancer Treatment Data
HCW Biologics stock rocketed on Monday after the company announced results from...
08-26 09:09
